<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02691741</url>
  </required_header>
  <id_info>
    <org_study_id>ILH297-P003</org_study_id>
    <nct_id>NCT02691741</nct_id>
  </id_info>
  <brief_title>Clinical Investigation of Visual Function After Bilateral Implantation of Two Presbyopia-Correcting Trifocal Intraocular Lenses (IOL)</brief_title>
  <official_title>Clinical Investigation of Visual Function After Bilateral Implantation of Two Presbyopia-Correcting Trifocal IOLs</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Alcon Research</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Alcon Research</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to clinically evaluate the visual performance of two
      commercially available presbyopia-correcting Trifocal IOLs.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Subjects will attend a total of 9 visits (6 postoperative) over a 7 month period.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 29, 2016</start_date>
  <completion_date type="Actual">July 17, 2017</completion_date>
  <primary_completion_date type="Actual">July 17, 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Least Squares Mean Binocular Uncorrected Intermediate Visual Acuity (UCIVA) (60cm) at Day 120-180</measure>
    <time_frame>Day 120-180 from second eye implantation</time_frame>
    <description>VA was tested binocularly (both eyes together) with no refractive correction in place using an early treatment diabetic retinopathy study (ETDRS) chart set at 60 cm. VA was measured in &quot;logarithm of the minimum angle of resolution&quot; (logMAR), with 0.1 logMAR increment corresponding to 5 letters, or 1 line, on an ETDRS chart. A lower numeric value represents better visual acuity.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Least Squares Mean Binocular UCIVA (60cm) at Day 120-180</measure>
    <time_frame>Day 120-180 from second eye implantation</time_frame>
    <description>VA was tested binocularly with no refractive correction in place using an ETDRS chart set at 60 cm. VA was measured in logMAR, with 0.1 logMAR increment corresponding to 5 letters, or 1 line, on an ETDRS chart. A lower numeric value represents better visual acuity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Least Squares Mean Binocular Uncorrected Distance VA (4m) at Day 120-180</measure>
    <time_frame>Day 120-180 from second eye implantation</time_frame>
    <description>VA was tested binocularly with no refractive correction in place using an ETDRS chart set at 4 meters. VA was measured in logMAR, with 0.1 logMAR increment corresponding to 5 letters, or 1 line, on an ETDRS chart. A lower numeric value represents better visual acuity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Least Squares Mean Binocular Uncorrected Near VA (40cm) at Day 120-180</measure>
    <time_frame>Day 120-180 from second eye implantation</time_frame>
    <description>VA was tested binocularly with no refractive correction in place using an ETDRS chart set at 40 cm. VA was measured in logMAR, with 0.1 logMAR increment corresponding to 5 letters, or 1 line, on an ETDRS chart. A lower numeric value represents better visual acuity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Photopic Binocular Defocus Curve at Day 120-180</measure>
    <time_frame>Day 120-180 from second eye implantation</time_frame>
    <description>A defocus curve is created by multiple measurements of one's visual acuity (VA) at different spherical powers. VA was measured in logMAR. A lower logMAR value indicates better visual acuity. No statistical test was performed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Photopic Without Glare Binocular Distance Contrast Sensitivity at Day 120-180</measure>
    <time_frame>Day 120-180 from second eye implantation</time_frame>
    <description>Contrast sensitivity (ie, the ability to detect slight changes in luminance before they become indistinguishable) was assessed binocularly in lighted conditions with distance manifest correction in place and uncorrected, with no glare source illumination. Contrast sensitivity was assessed at spatial frequencies of 3, 6, 12, and 18 cycles per degree (CPD) and reported in log units. A higher numeric value represents better contrast sensitivity. No statistical test was performed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Photopic With Glare Binocular Distance Contrast Sensitivity at Day 120-180</measure>
    <time_frame>Day 120-180 from second eye implantation</time_frame>
    <description>Contrast sensitivity (ie, the ability to detect slight changes in luminance before they become indistinguishable) was assessed binocularly in lighted conditions with distance manifest correction in place and uncorrected, with glare source illumination. Contrast sensitivity was assessed at spatial frequencies of 3, 6, 12, and 18 CPDs and reported in log units. A higher numeric value represents better contrast sensitivity. No statistical test was performed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Mesopic Without Glare Binocular Distance Contrast Sensitivity at Day 120-180</measure>
    <time_frame>Day 120-180 from second eye implantation</time_frame>
    <description>Contrast sensitivity (ie, the ability to detect slight changes in luminance before they become indistinguishable) was assessed binocularly in dim to dark conditions with distance manifest correction in place and uncorrected, with no glare source illumination. Contrast sensitivity was assessed at spatial frequencies of 1.5, 3, 6, and 12 CPDs and reported in log units. A higher numeric value represents better contrast sensitivity. No statistical test was performed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Mesopic With Glare Binocular Distance Contrast Sensitivity at Day 120-180</measure>
    <time_frame>Day 120-180 from second eye implantation</time_frame>
    <description>Contrast sensitivity (ie, the ability to detect slight changes in luminance before they become indistinguishable) was assessed binocularly with distance manifest correction in place and uncorrected, with glare source illumination. Contrast sensitivity was assessed at spatial frequencies of 1.5, 3, 6, and 12 CPDs and reported in log units. A higher numeric value represents better contrast sensitivity. No statistical test was performed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subject Satisfaction Recorded at Day 120-180</measure>
    <time_frame>Day 120-180 from second eye implantation</time_frame>
    <description>At the Month 6 Visit, subjects responded to the question: &quot;Given your current postoperative vision, if you had to do it all over would you have the same lens implanted again?&quot;. Responses were reported as a percentage of subjects. No statistical test was performed.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">215</enrollment>
  <condition>Cataracts</condition>
  <arm_group>
    <arm_group_label>TFNT00</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AcrySof® IQ PanOptix™ Presbyopia-Correcting IOL, bilateral implantation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>839MP</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>AT LISA® tri IOL, bilateral implantation</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>AcrySof® IQ PanOptix™ Presbyopia-Correcting IOL</intervention_name>
    <description>Trifocal IOL(near, intermediate, distance) implanted for long-term use over the lifetime of the cataract patient</description>
    <arm_group_label>TFNT00</arm_group_label>
    <other_name>Model TFNT00</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>AT LISA® tri IOL</intervention_name>
    <description>Trifocal IOL(near, intermediate, distance) implanted for long-term use over the lifetime of the cataract patient</description>
    <arm_group_label>839MP</arm_group_label>
    <other_name>Model 839MP</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of bilateral cataracts with planned clear cornea cataract removal;

          -  Able to comprehend and willing to sign informed consent and complete all required
             postoperative follow-up procedures;

          -  Calculated lens power between 13.0 and 30.0 Diopters (D);

          -  Preoperative Best-corrected distance visual acuity (BCDVA) worse than 0.20 logMAR (ie,
             0.22 logMAR or worse) in at least one eye;

          -  Potential postoperative BCDVA of 0.20 logMAR or better in both eyes. Note: Subjects
             with any pathology that could reduce visual potential should not be enrolled in this
             trial;

          -  Preoperative regular corneal astigmatism of &lt; 1.00 D, in both eyes;

          -  Clear intraocular media other than cataract in both eyes;

          -  Other protocol-specified inclusion criteria may apply.

        Exclusion Criteria:

          -  Reasonably expected to require an ocular surgical treatment at any time during the
             study (other than YAG capsulotomy);

          -  Previous refractive surgery or planned refractive surgery procedures throughout the
             entire duration of participation in the clinical study (including, but not limited to
             LASIK, astigmatic keratotomy and limbal relaxing incisions);

          -  Clinically significant corneal abnormalities including corneal dystrophy, inflammation
             or edema;

          -  Amblyopia;

          -  Previous corneal transplant;

          -  Any recurrent severe anterior or posterior segment inflammation of any etiology,
             and/or history of any disease producing an intraocular inflammatory reaction;

          -  Rubella, congenital, traumatic, or complicated cataracts;

          -  Glaucoma (uncontrolled or controlled with medication);

          -  Degenerative eye disorders;

          -  History of or current retinal conditions or predisposition to retinal conditions,
             previous history of, or a predisposition to, retinal detachment or presence of
             diabetic retinopathy;

          -  Optic nerve atrophy;

          -  Expected to require retinal laser treatment;

          -  Color vision deficiencies;

          -  Pregnant or lactating (current or planned during the course of the study);

          -  Other protocol-specified exclusion criteria may apply.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>22 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sr. Clinical Manager, GCRA</last_name>
    <role>Study Director</role>
    <affiliation>Alcon, a Novartis Company</affiliation>
  </overall_official>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>February 22, 2016</study_first_submitted>
  <study_first_submitted_qc>February 22, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 25, 2016</study_first_posted>
  <results_first_submitted>August 30, 2019</results_first_submitted>
  <results_first_submitted_qc>September 25, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">September 27, 2019</results_first_posted>
  <disposition_first_submitted>July 3, 2018</disposition_first_submitted>
  <disposition_first_submitted_qc>July 3, 2018</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">September 27, 2019</disposition_first_posted>
  <last_update_submitted>September 25, 2019</last_update_submitted>
  <last_update_submitted_qc>September 25, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 27, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cataract</mesh_term>
    <mesh_term>Presbyopia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>July 12, 2016</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/41/NCT02691741/SAP_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>February 24, 2016</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/41/NCT02691741/Prot_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Subjects were recruited from 15 study centers located in Australia (3), Brazil (3), Spain (3), Denmark (2), Colombia (2), United Kingdom (1), and the Netherlands (1).</recruitment_details>
      <pre_assignment_details>Of the 215 enrolled, 26 subjects were exited as screen failures and 1 subject died prior to randomization. This reporting group includes all randomized subjects (188).</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>TFNT00</title>
          <description>AcrySof® IQ PanOptix™ Presbyopia-Correcting IOL, bilateral implantation</description>
        </group>
        <group group_id="P2">
          <title>839MP</title>
          <description>AT LISA® tri IOL, bilateral implantation</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="94"/>
                <participants group_id="P2" count="94"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>All-Implanted Analysis Set</title>
              <participants_list>
                <participants group_id="P1" count="93"/>
                <participants group_id="P2" count="89"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Best-Case Analysis Set</title>
              <participants_list>
                <participants group_id="P1" count="86"/>
                <participants group_id="P2" count="85"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Safety Analysis Set</title>
              <participants_list>
                <participants group_id="P1" count="93"/>
                <participants group_id="P2" count="89"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="93"/>
                <participants group_id="P2" count="87"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>All-Implanted Analysis Set</population>
      <group_list>
        <group group_id="B1">
          <title>TFNT00</title>
          <description>AcrySof® IQ PanOptix™ Presbyopia-Correcting IOL, bilateral implantation</description>
        </group>
        <group group_id="B2">
          <title>839MP</title>
          <description>AT LISA® tri IOL, bilateral implantation</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="93"/>
            <count group_id="B2" value="89"/>
            <count group_id="B3" value="182"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="66.1" spread="9.29"/>
                    <measurement group_id="B2" value="65.6" spread="9.56"/>
                    <measurement group_id="B3" value="65.9" spread="9.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="57"/>
                    <measurement group_id="B2" value="55"/>
                    <measurement group_id="B3" value="112"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="36"/>
                    <measurement group_id="B2" value="34"/>
                    <measurement group_id="B3" value="70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Race/Ethnicity</title>
              <category_list>
                <category>
                  <title>White or Caucasian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="42"/>
                    <measurement group_id="B2" value="39"/>
                    <measurement group_id="B3" value="81"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="11"/>
                  </measurement_list>
                </category>
                <category>
                  <title>American Indian or Native American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Multi-Racial</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Other</title>
                  <measurement_list>
                    <measurement group_id="B1" value="44"/>
                    <measurement group_id="B2" value="38"/>
                    <measurement group_id="B3" value="82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Least Squares Mean Binocular Uncorrected Intermediate Visual Acuity (UCIVA) (60cm) at Day 120-180</title>
        <description>VA was tested binocularly (both eyes together) with no refractive correction in place using an early treatment diabetic retinopathy study (ETDRS) chart set at 60 cm. VA was measured in &quot;logarithm of the minimum angle of resolution&quot; (logMAR), with 0.1 logMAR increment corresponding to 5 letters, or 1 line, on an ETDRS chart. A lower numeric value represents better visual acuity.</description>
        <time_frame>Day 120-180 from second eye implantation</time_frame>
        <population>All-Implanted Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>TFNT00</title>
            <description>AcrySof® IQ PanOptix™ Presbyopia-Correcting IOL, bilateral implantation</description>
          </group>
          <group group_id="O2">
            <title>839MP</title>
            <description>AT LISA® tri IOL, bilateral implantation</description>
          </group>
        </group_list>
        <measure>
          <title>Least Squares Mean Binocular Uncorrected Intermediate Visual Acuity (UCIVA) (60cm) at Day 120-180</title>
          <description>VA was tested binocularly (both eyes together) with no refractive correction in place using an early treatment diabetic retinopathy study (ETDRS) chart set at 60 cm. VA was measured in &quot;logarithm of the minimum angle of resolution&quot; (logMAR), with 0.1 logMAR increment corresponding to 5 letters, or 1 line, on an ETDRS chart. A lower numeric value represents better visual acuity.</description>
          <population>All-Implanted Analysis Set</population>
          <units>logMAR</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="93"/>
                <count group_id="O2" value="89"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.053" spread="0.0134"/>
                    <measurement group_id="O2" value="0.115" spread="0.0139"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority is demonstrated if the upper confidence limit of the two-sided 90% confidence interval on the treatment difference is less than 0.1 logMAR unit.</non_inferiority_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.061</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.0193</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.093</ci_lower_limit>
            <ci_upper_limit>-0.029</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Least Squares Mean Binocular UCIVA (60cm) at Day 120-180</title>
        <description>VA was tested binocularly with no refractive correction in place using an ETDRS chart set at 60 cm. VA was measured in logMAR, with 0.1 logMAR increment corresponding to 5 letters, or 1 line, on an ETDRS chart. A lower numeric value represents better visual acuity.</description>
        <time_frame>Day 120-180 from second eye implantation</time_frame>
        <population>All-Implanted Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>TFNT00</title>
            <description>AcrySof® IQ PanOptix™ Presbyopia-Correcting IOL, bilateral implantation</description>
          </group>
          <group group_id="O2">
            <title>839MP</title>
            <description>AT LISA® tri IOL, bilateral implantation</description>
          </group>
        </group_list>
        <measure>
          <title>Least Squares Mean Binocular UCIVA (60cm) at Day 120-180</title>
          <description>VA was tested binocularly with no refractive correction in place using an ETDRS chart set at 60 cm. VA was measured in logMAR, with 0.1 logMAR increment corresponding to 5 letters, or 1 line, on an ETDRS chart. A lower numeric value represents better visual acuity.</description>
          <population>All-Implanted Analysis Set</population>
          <units>logMAR</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="93"/>
                <count group_id="O2" value="89"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.053" spread="0.0134"/>
                    <measurement group_id="O2" value="0.115" spread="0.0139"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.002</p_value>
            <method>Repeated Measures Analysis of Variance</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.061</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.0193</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.093</ci_lower_limit>
            <ci_upper_limit>-0.029</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Least Squares Mean Binocular Uncorrected Distance VA (4m) at Day 120-180</title>
        <description>VA was tested binocularly with no refractive correction in place using an ETDRS chart set at 4 meters. VA was measured in logMAR, with 0.1 logMAR increment corresponding to 5 letters, or 1 line, on an ETDRS chart. A lower numeric value represents better visual acuity.</description>
        <time_frame>Day 120-180 from second eye implantation</time_frame>
        <population>All-Implanted Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>TFNT00</title>
            <description>AcrySof® IQ PanOptix™ Presbyopia-Correcting IOL, bilateral implantation</description>
          </group>
          <group group_id="O2">
            <title>839MP</title>
            <description>AT LISA® tri IOL, bilateral implantation</description>
          </group>
        </group_list>
        <measure>
          <title>Least Squares Mean Binocular Uncorrected Distance VA (4m) at Day 120-180</title>
          <description>VA was tested binocularly with no refractive correction in place using an ETDRS chart set at 4 meters. VA was measured in logMAR, with 0.1 logMAR increment corresponding to 5 letters, or 1 line, on an ETDRS chart. A lower numeric value represents better visual acuity.</description>
          <population>All-Implanted Analysis Set</population>
          <units>logMAR</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="93"/>
                <count group_id="O2" value="89"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.015" spread="0.0109"/>
                    <measurement group_id="O2" value="0.004" spread="0.0113"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority is demonstrated if the upper confidence limit of the two-sided 90% confidence interval on the treatment difference is less than 0.1 logMAR unit.</non_inferiority_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.012</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.0157</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.019</ci_lower_limit>
            <ci_upper_limit>0.043</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.455</p_value>
            <method>Repeated Measures Analysis of Variance</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Least Squares Mean Binocular Uncorrected Near VA (40cm) at Day 120-180</title>
        <description>VA was tested binocularly with no refractive correction in place using an ETDRS chart set at 40 cm. VA was measured in logMAR, with 0.1 logMAR increment corresponding to 5 letters, or 1 line, on an ETDRS chart. A lower numeric value represents better visual acuity.</description>
        <time_frame>Day 120-180 from second eye implantation</time_frame>
        <population>All-Implanted Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>TFNT00</title>
            <description>AcrySof® IQ PanOptix™ Presbyopia-Correcting IOL, bilateral implantation</description>
          </group>
          <group group_id="O2">
            <title>839MP</title>
            <description>AT LISA® tri IOL, bilateral implantation</description>
          </group>
        </group_list>
        <measure>
          <title>Least Squares Mean Binocular Uncorrected Near VA (40cm) at Day 120-180</title>
          <description>VA was tested binocularly with no refractive correction in place using an ETDRS chart set at 40 cm. VA was measured in logMAR, with 0.1 logMAR increment corresponding to 5 letters, or 1 line, on an ETDRS chart. A lower numeric value represents better visual acuity.</description>
          <population>All-Implanted Analysis Set</population>
          <units>logMAR</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="93"/>
                <count group_id="O2" value="89"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.083" spread="0.0116"/>
                    <measurement group_id="O2" value="0.133" spread="0.0121"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority is demonstrated if the upper confidence limit of the two-sided 90% confidence interval on the treatment difference is less than 0.1 logMAR unit.</non_inferiority_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.051</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.0168</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.078</ci_lower_limit>
            <ci_upper_limit>-0.023</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.003</p_value>
            <method>Repeated Measures Analysis of Variance</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Photopic Binocular Defocus Curve at Day 120-180</title>
        <description>A defocus curve is created by multiple measurements of one's visual acuity (VA) at different spherical powers. VA was measured in logMAR. A lower logMAR value indicates better visual acuity. No statistical test was performed.</description>
        <time_frame>Day 120-180 from second eye implantation</time_frame>
        <population>This analysis population includes all subjects with eyes successfully implanted with the test or control article that had at least one postoperative visit, and with no macular degeneration at any time, and no major protocol deviations (Best-Case Analysis Set), with data available.</population>
        <group_list>
          <group group_id="O1">
            <title>TFNT00</title>
            <description>AcrySof® IQ PanOptix™ Presbyopia-Correcting IOL, bilateral implantation</description>
          </group>
          <group group_id="O2">
            <title>839MP</title>
            <description>AT LISA® tri IOL, bilateral implantation</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Photopic Binocular Defocus Curve at Day 120-180</title>
          <description>A defocus curve is created by multiple measurements of one's visual acuity (VA) at different spherical powers. VA was measured in logMAR. A lower logMAR value indicates better visual acuity. No statistical test was performed.</description>
          <population>This analysis population includes all subjects with eyes successfully implanted with the test or control article that had at least one postoperative visit, and with no macular degeneration at any time, and no major protocol deviations (Best-Case Analysis Set), with data available.</population>
          <units>logMAR</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="86"/>
                <count group_id="O2" value="81"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>0.0 Diopter (D)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.048" spread="0.0811"/>
                    <measurement group_id="O2" value="-0.069" spread="0.0831"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>-0.5D</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.016" spread="0.0835"/>
                    <measurement group_id="O2" value="-0.018" spread="0.0951"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>-1.0D</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.093" spread="0.0993"/>
                    <measurement group_id="O2" value="0.048" spread="0.1207"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>-1.5D</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.038" spread="0.0983"/>
                    <measurement group_id="O2" value="0.084" spread="0.1111"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>-2.0D</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.011" spread="0.0859"/>
                    <measurement group_id="O2" value="0.117" spread="0.1039"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>-2.5D</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.027" spread="0.1013"/>
                    <measurement group_id="O2" value="0.063" spread="0.1399"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>-3.0D</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.118" spread="0.1297"/>
                    <measurement group_id="O2" value="0.077" spread="0.1241"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>-3.5D</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.231" spread="0.1252"/>
                    <measurement group_id="O2" value="0.206" spread="0.1415"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>-4.0D</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.338" spread="0.1319"/>
                    <measurement group_id="O2" value="0.364" spread="0.1302"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>-4.5D</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.469" spread="0.1417"/>
                    <measurement group_id="O2" value="0.532" spread="0.1240"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>-5.0D</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.586" spread="0.1292"/>
                    <measurement group_id="O2" value="0.644" spread="0.1048"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Photopic Without Glare Binocular Distance Contrast Sensitivity at Day 120-180</title>
        <description>Contrast sensitivity (ie, the ability to detect slight changes in luminance before they become indistinguishable) was assessed binocularly in lighted conditions with distance manifest correction in place and uncorrected, with no glare source illumination. Contrast sensitivity was assessed at spatial frequencies of 3, 6, 12, and 18 cycles per degree (CPD) and reported in log units. A higher numeric value represents better contrast sensitivity. No statistical test was performed.</description>
        <time_frame>Day 120-180 from second eye implantation</time_frame>
        <population>Best-Case Analysis Set, with available data</population>
        <group_list>
          <group group_id="O1">
            <title>TFNT00</title>
            <description>AcrySof® IQ PanOptix™ Presbyopia-Correcting IOL, bilateral implantation</description>
          </group>
          <group group_id="O2">
            <title>839MP</title>
            <description>AT LISA® tri IOL, bilateral implantation</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Photopic Without Glare Binocular Distance Contrast Sensitivity at Day 120-180</title>
          <description>Contrast sensitivity (ie, the ability to detect slight changes in luminance before they become indistinguishable) was assessed binocularly in lighted conditions with distance manifest correction in place and uncorrected, with no glare source illumination. Contrast sensitivity was assessed at spatial frequencies of 3, 6, 12, and 18 cycles per degree (CPD) and reported in log units. A higher numeric value represents better contrast sensitivity. No statistical test was performed.</description>
          <population>Best-Case Analysis Set, with available data</population>
          <units>log units</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="86"/>
                <count group_id="O2" value="81"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>3 CPD</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.720" spread="0.2025"/>
                    <measurement group_id="O2" value="1.735" spread="0.1894"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 CPD</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.860" spread="0.2635"/>
                    <measurement group_id="O2" value="1.831" spread="0.2699"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 CPD</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.482" spread="0.3853"/>
                    <measurement group_id="O2" value="1.496" spread="0.4328"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>18 CPD</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.021" spread="0.3778"/>
                    <measurement group_id="O2" value="1.022" spread="0.4197"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Photopic With Glare Binocular Distance Contrast Sensitivity at Day 120-180</title>
        <description>Contrast sensitivity (ie, the ability to detect slight changes in luminance before they become indistinguishable) was assessed binocularly in lighted conditions with distance manifest correction in place and uncorrected, with glare source illumination. Contrast sensitivity was assessed at spatial frequencies of 3, 6, 12, and 18 CPDs and reported in log units. A higher numeric value represents better contrast sensitivity. No statistical test was performed.</description>
        <time_frame>Day 120-180 from second eye implantation</time_frame>
        <population>Best-Case Analysis Set, with data available</population>
        <group_list>
          <group group_id="O1">
            <title>TFNT00</title>
            <description>AcrySof® IQ PanOptix™ Presbyopia-Correcting IOL, bilateral implantation</description>
          </group>
          <group group_id="O2">
            <title>839MP</title>
            <description>AT LISA® tri IOL, bilateral implantation</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Photopic With Glare Binocular Distance Contrast Sensitivity at Day 120-180</title>
          <description>Contrast sensitivity (ie, the ability to detect slight changes in luminance before they become indistinguishable) was assessed binocularly in lighted conditions with distance manifest correction in place and uncorrected, with glare source illumination. Contrast sensitivity was assessed at spatial frequencies of 3, 6, 12, and 18 CPDs and reported in log units. A higher numeric value represents better contrast sensitivity. No statistical test was performed.</description>
          <population>Best-Case Analysis Set, with data available</population>
          <units>log units</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="86"/>
                <count group_id="O2" value="81"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>3 CPD</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.721" spread="0.2041"/>
                    <measurement group_id="O2" value="1.754" spread="0.2225"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 CPD</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.790" spread="0.3282"/>
                    <measurement group_id="O2" value="1.797" spread="0.3538"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 CPD</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.434" spread="0.4616"/>
                    <measurement group_id="O2" value="1.426" spread="0.4570"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>18 CPD</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.007" spread="0.3769"/>
                    <measurement group_id="O2" value="1.033" spread="0.4316"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Mesopic Without Glare Binocular Distance Contrast Sensitivity at Day 120-180</title>
        <description>Contrast sensitivity (ie, the ability to detect slight changes in luminance before they become indistinguishable) was assessed binocularly in dim to dark conditions with distance manifest correction in place and uncorrected, with no glare source illumination. Contrast sensitivity was assessed at spatial frequencies of 1.5, 3, 6, and 12 CPDs and reported in log units. A higher numeric value represents better contrast sensitivity. No statistical test was performed.</description>
        <time_frame>Day 120-180 from second eye implantation</time_frame>
        <population>Best-Case Analysis Set with data available</population>
        <group_list>
          <group group_id="O1">
            <title>TFNT00</title>
            <description>AcrySof® IQ PanOptix™ Presbyopia-Correcting IOL, bilateral implantation</description>
          </group>
          <group group_id="O2">
            <title>839MP</title>
            <description>AT LISA® tri IOL, bilateral implantation</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Mesopic Without Glare Binocular Distance Contrast Sensitivity at Day 120-180</title>
          <description>Contrast sensitivity (ie, the ability to detect slight changes in luminance before they become indistinguishable) was assessed binocularly in dim to dark conditions with distance manifest correction in place and uncorrected, with no glare source illumination. Contrast sensitivity was assessed at spatial frequencies of 1.5, 3, 6, and 12 CPDs and reported in log units. A higher numeric value represents better contrast sensitivity. No statistical test was performed.</description>
          <population>Best-Case Analysis Set with data available</population>
          <units>log units</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="86"/>
                <count group_id="O2" value="81"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>1.5 CPD</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.611" spread="0.2293"/>
                    <measurement group_id="O2" value="1.600" spread="0.2226"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 CPD</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.648" spread="0.3115"/>
                    <measurement group_id="O2" value="1.682" spread="0.2639"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 CPD</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.667" spread="0.4284"/>
                    <measurement group_id="O2" value="1.676" spread="0.4243"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 CPD</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.208" spread="0.5262"/>
                    <measurement group_id="O2" value="1.227" spread="0.5307"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Mesopic With Glare Binocular Distance Contrast Sensitivity at Day 120-180</title>
        <description>Contrast sensitivity (ie, the ability to detect slight changes in luminance before they become indistinguishable) was assessed binocularly with distance manifest correction in place and uncorrected, with glare source illumination. Contrast sensitivity was assessed at spatial frequencies of 1.5, 3, 6, and 12 CPDs and reported in log units. A higher numeric value represents better contrast sensitivity. No statistical test was performed.</description>
        <time_frame>Day 120-180 from second eye implantation</time_frame>
        <population>Best-Case Analysis Set, with data available</population>
        <group_list>
          <group group_id="O1">
            <title>TFNT00</title>
            <description>AcrySof® IQ PanOptix™ Presbyopia-Correcting IOL, bilateral implantation</description>
          </group>
          <group group_id="O2">
            <title>839MP</title>
            <description>AT LISA® tri IOL, bilateral implantation</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Mesopic With Glare Binocular Distance Contrast Sensitivity at Day 120-180</title>
          <description>Contrast sensitivity (ie, the ability to detect slight changes in luminance before they become indistinguishable) was assessed binocularly with distance manifest correction in place and uncorrected, with glare source illumination. Contrast sensitivity was assessed at spatial frequencies of 1.5, 3, 6, and 12 CPDs and reported in log units. A higher numeric value represents better contrast sensitivity. No statistical test was performed.</description>
          <population>Best-Case Analysis Set, with data available</population>
          <units>log units</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="86"/>
                <count group_id="O2" value="81"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>1.5 CPD</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.579" spread="0.2581"/>
                    <measurement group_id="O2" value="1.538" spread="0.2568"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 CPD</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.642" spread="0.2696"/>
                    <measurement group_id="O2" value="1.682" spread="0.2642"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 CPD</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.550" spread="0.4791"/>
                    <measurement group_id="O2" value="1.607" spread="0.4898"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 CPD</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.146" spread="0.5623"/>
                    <measurement group_id="O2" value="1.175" spread="0.6062"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Subject Satisfaction Recorded at Day 120-180</title>
        <description>At the Month 6 Visit, subjects responded to the question: &quot;Given your current postoperative vision, if you had to do it all over would you have the same lens implanted again?&quot;. Responses were reported as a percentage of subjects. No statistical test was performed.</description>
        <time_frame>Day 120-180 from second eye implantation</time_frame>
        <population>All-Implanted Analysis Set with data available</population>
        <group_list>
          <group group_id="O1">
            <title>TFNT00</title>
            <description>AcrySof® IQ PanOptix™ Presbyopia-Correcting IOL, bilateral implantation</description>
          </group>
          <group group_id="O2">
            <title>839MP</title>
            <description>AT LISA® tri IOL, bilateral implantation</description>
          </group>
        </group_list>
        <measure>
          <title>Subject Satisfaction Recorded at Day 120-180</title>
          <description>At the Month 6 Visit, subjects responded to the question: &quot;Given your current postoperative vision, if you had to do it all over would you have the same lens implanted again?&quot;. Responses were reported as a percentage of subjects. No statistical test was performed.</description>
          <population>All-Implanted Analysis Set with data available</population>
          <units>percentage of subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="93"/>
                <count group_id="O2" value="87"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95.7"/>
                    <measurement group_id="O2" value="96.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.2"/>
                    <measurement group_id="O2" value="2.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Missing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.1"/>
                    <measurement group_id="O2" value="1.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>IOL implantation through study completion, an average of 7 months</time_frame>
      <desc>An adverse event (AE) was defined as any untoward medical occurrence, unintended disease or injury, or untoward clinical signs in subjects, users or other persons, whether or not related to the medical device. AEs were obtained through solicited comments from subjects by the Investigators. Safety Analysis Set. &quot;At risk&quot; population for ocular AEs is reported in units of eyes.</desc>
      <group_list>
        <group group_id="E1">
          <title>TFNT00 - 1st Eye</title>
          <description>First eye implanted with AcrySof® IQ PanOptix™ Presbyopia-Correcting IOL</description>
        </group>
        <group group_id="E2">
          <title>TFNT00 - 2nd Eye</title>
          <description>Second eye implanted with AcrySof® IQ PanOptix™ Presbyopia-Correcting IOL</description>
        </group>
        <group group_id="E3">
          <title>TFNT00 - Systemic</title>
          <description>Subjects implanted with AcrySof® IQ PanOptix™ Presbyopia-Correcting IOL in at least one eye</description>
        </group>
        <group group_id="E4">
          <title>839MP - 1st Eye</title>
          <description>First eye implanted with AT LISA® tri IOL</description>
        </group>
        <group group_id="E5">
          <title>839MP - 2nd Eye</title>
          <description>Second eye implanted with AT LISA® tri IOL</description>
        </group>
        <group group_id="E6">
          <title>839MP - Non-Study Eye</title>
          <description>Eyes not meeting study inclusion/exclusion criteria</description>
        </group>
        <group group_id="E7">
          <title>839MP - Systemic</title>
          <description>Subjects implanted with AT LISA® tri IOL in at least one eye</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (19.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="89"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="93"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="89"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="87"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="89"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Cystoid macular oedema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="89"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="87"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="89"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="93"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="89"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Product Issues</title>
            <event_list>
              <event>
                <sub_title>Device dislocation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="89"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="89"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="93"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="89"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Intra-ocular injection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="89"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="87"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="89"/>
              </event>
              <event>
                <sub_title>Intraocular lens implant</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="89"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="89"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (19.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="93"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="93"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="89"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="87"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="89"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Halo vision</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="93"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="93"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="89"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="87"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="89"/>
              </event>
              <event>
                <sub_title>Posterior capsule opacification</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="93"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="93"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="89"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="87"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="89"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Sponsor reserves the right of prior review of any publication or presentation of information related to the study.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Sr. Global Brand Medical Affairs Lead, CDMA Surgical</name_or_title>
      <organization>Alcon, A Novartis Division</organization>
      <phone>1-888-451-3937</phone>
      <email>alcon.medinfo@alcon.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

